Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06148272 · ClinicalTrials.gov registry record · Phase 1

A Study of LY3971297 in Healthy Participants

A Phase 1 study of Healthy and Obesity, sponsored by Eli Lilly and Company.

Recruiting
Registry status
Phase 1
Development phase
225
Enrollment target
7
Study locations

NCT06148272: Recruiting Phase 1 study of Healthy and Obesity, sponsored by Eli Lilly and Company.

NCT06148272 is a Phase 1 study of Healthy and Obesity that is actively recruiting participants, run by Eli Lilly and Company. The registered enrollment target is 225 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (65% lower). The trial reports 7 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06148272, a Phase 1 study of Healthy and Obesity, is actively recruiting participants, sponsored by Eli Lilly and Company.

RECRUITING
Registry status
Phase 1
Development phase
225 participants
Enrollment target
7
Study locations

Study Summary

The purpose of this study is to measure side effects of LY3971297 injection administered under the skin in healthy participants and obese participants with high blood pressure (BP). Blood tests will be performed to check how much LY3971297 gets into the bloodstream and how long it takes the body to eliminate it. This is a 7-part study. The study duration will be approximately 60 days for Parts A and F, and approximately 90 days for Parts B, C, D, E, and G.

Primary Outcome

Part A and F: A summary of TEAEs and SAEs, regardless of causality, will be reported in the Reported Adverse Events module

Interventions

  • DRUG Placebo
  • DRUG LY3971297
  • DRUG LY3971297 IV

Study Locations (7)

Other

  • Hakata Clinic - Fukuoka
  • P-One Clinic - Hachiōji
  • Clinical Research Hospital Tokyo - Shinjuku-ku
  • Lilly Centre for Clinical Pharmacology - Singapore

California

  • CenExel ACT - Anaheim

Florida

  • Clinical Pharmacology of Miami - Miami

Texas

  • ICON Early Phase Services - San Antonio

Trial Details

FieldValue
Enrollment Target 225 participants
Start Date 2023-12-07
Est. Completion 2026-09
Phase Phase 1
Eli Lilly and Company

1,341 total trials

What NCT06148272 shows while recruiting

NCT06148272 is an interventional study that assigns participants to a tested intervention. The registered 225 participants enrollment target is mid-sized for trials with a published cap, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (65% lower).

The record links to 3 conditions, with Healthy appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.

NCT06148272 lists 7 locations in 4 states (Other, California, Florida).

Frequently Asked Questions

What is clinical trial NCT06148272 about?

NCT06148272 is a clinical study titled "A Study of LY3971297 in Healthy Participants". The purpose of this study is to measure side effects of LY3971297 injection administered under the skin in healthy participants and obese participants with high blood pressure (BP). Blood tests will be performed to check how much LY3971297 gets into the bloodstream and how long it takes the body to ...

What is the current status of trial NCT06148272?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 225 participants. The study started on 2023-12-07. Estimated completion is 2026-09.

What conditions does trial NCT06148272 study?

This clinical trial studies the following conditions: Healthy, Obesity, Hypertension.

What interventions are being tested in trial NCT06148272?

The interventions under investigation include: Placebo (DRUG), LY3971297 (DRUG), LY3971297 IV (DRUG).

Who is sponsoring clinical trial NCT06148272?

This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06148272 being conducted?

This trial has 7 study locations across California, Florida, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06148272's enrollment target sits among peer trials

225 109th of 1090 higher than 981 of 1,090 other Healthy trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Healthy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03955445 · 225 participants · Phase 3

    Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN

  • NCT04054310 · 225 participants · NA

    Non-Invasive Quantification of Liver Health in NASH (N-QUAN)

  • NCT04480554 · 225 participants · Phase 2

    Anti-retroviral Therapy, Medications for Opioid Use Disorder, Opioids and HIV Infection - Study 1

  • NCT04888104 · 225 participants

    Prospective, Multicenter, Case-Control Analysis of the VersaTie Posterior Fixation System to Prevent Proximal Junctional Failure in Long Posterior Spinal Fusion Constructs for Adult Patients

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06148272, the US trial registry maintained by the National Library of Medicine. NCT06148272 (mid enrollment · multi site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.